OMER•benzinga•
FDA Accepts Omeros' Biologics License Application For Narsoplimab In Transplant-Associated Thrombotic Microangiopathy
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 6, 2025 by benzinga